Non Invasive And Invasive Technologies For Translational Medicine Applications | 18738
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 3463

Journal of Analytical & Bioanalytical Techniques received 3463 citations as per Google Scholar report

Journal of Analytical & Bioanalytical Techniques peer review process verified at publons
Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • OCLC- WorldCat
  • Scholarsteer
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Euro Pub
Share This Page

Non invasive and invasive technologies for translational medicine applications

5th International Conference and Exhibition on Analytical & Bioanalytical Techniques

Francesco Crespi

Accepted Abstracts: J Anal Bioanal Tech

DOI: 10.4172/2155-9872.S1.019

In preclinical studies, the feasibility of non-invasive analysis of brain activities is studied in the attempt to overcome the major limitation of actual in vivo methodologies i.e. invasiveness. Near-infrared spectroscopy (NIRS) is a non-invasive technique that can be used to monitor changes in oxygenation of hemoglobin (Hb). Importantly, the absorption spectra of near-infrared light differ for the oxygenation-deoxygenation states of Hb (O 2 Hb vs. HHb, respectively) so that the two compounds can be directly monitored. The sum of HHb + O 2 Hb is considered = blood volume and a recent work has demonstrated the feasibility of using NIRS to monitor these three parameters in the rat brain. Briefly, the effectiveness of such non-invasive methodology in preclinical studies has been tested via physiologic (i.e. with exogenous oxygen (O 2 ) or carbon dioxide (CO 2 ) inflated orally?) or pharmacologic (i.e. with drugs of abuse such as cocaine or nicotine) experiments. Furthermore, coupling NIRS with a well established although invasive in vivo method such as electrophysiology allowing concomitant analysis of cerebral cell firing in discrete brain areas, was confirming the putative correlation between blood levels, brain metabolism and neuronal activities in rat CNS. Finally, the possibility that changes in brain metabolism as measured by NIRS might be a useful index of brain penetration of chemical entities has been investigated using different compounds from different chemical classes that were selected on the basis of their known brain penetration and overall pharmacokinetic profile. It appeared that in vivo non-invasive NIRS might contribute to assess brain penetration of chemicals, i.e. significant changes in NIRS signals could be related to brain exposure, or vice versa the lack of significant changes in relevant NIRS parameters could be indicative of low brain exposure. These data were supported by concomitant standard pharmacokinetic studies of brain penetration. Further improvement of NIRS hardware and software will allow shaping also the distribution of penetrating drugs within discrete brain areas and this could be potentially used to study neurobiological processes and psychiatric diseases in preclinical but also in a translational strategy from preclinical to clinical investigations.
Francesco Crespi has initiated his research work at the Istituto M Negri, Milano, Italy and completed a French PhD from Toulouse University (F) and an English PhD from Nottingham University (U.K.). With the role of Principal Research Scientist in GSK he has developed advanced technologies to study psychiatric disorders. He has published more than 100 papers in reputed journals and has been serving as an editorial board member of repute.